Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 5/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23471218 | 0.91 | NAMPT (0.47) | ALDH1A1TSHRCASP1CASP7HSD17B10 | |
| SCHEMBL20463075 | 0.84 | TSHR (0.50) | ALDH1A1TSHRCASP1CASP7HSD17B10 | |
| SCHEMBL15942670 | 0.84 | MEN1 (0.59) | ALDH1A1TSHRCASP1CASP7HSD17B10 | |
| SCHEMBL13034763 | 0.83 | TSHR (0.43) | ALDH1A1TSHRCASP1CASP7HSD17B10 | |
| SCHEMBL25883434 | 0.83 | EPHX2 (0.49) | ALDH1A1TSHRCASP1CASP7HSD17B10 | |
| SCHEMBL25887731 | 0.82 | MEN1 (0.57) | ALDH1A1TSHRCASP1CASP7HSD17B10 | |
| SCHEMBL20463275 | 0.81 | TSHR (0.47) | ALDH1A1TSHRCASP1CASP7HSD17B10 | |
| SCHEMBL23842182 | 0.81 | MEN1 (0.57) | ALDH1A1TSHRCASP1CASP7HSD17B10 | |
| SCHEMBL26551714 | 0.80 | TSHR (0.44) | ALDH1A1TSHRCASP1CASP7HSD17B10 | |
| SCHEMBL21105956 | 0.80 | FAAH (0.57) | ALDH1A1TSHRRECQLNAMPTEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10646575-B2 | Heterocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190076541-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10646575-B2 | Heterocyclic degronimers for target protein degradation | CRBN, MDM2, STUB1 | ALDH1A1 4029/4885TSHR 460/4885CASP1 3084/4885 |
| US-20190076541-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | ALDH1A1 4029/4885TSHR 460/4885CASP1 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.